This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schinke, M. Articles by Bader, M. Search for Related Content PubMed PubMed Citation Articles by Schinke, M. Articles by Bader, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Hypertension. 1996;27:508-513.)
© 1996 American Heart Association, Inc.

Articles

Permanent Inhibition of Angiotensinogen Synthesis by Antisense RNA Expression

Martina Schinke; Manfred Böhm; Giampiero Bricca; Detlev Ganten; Michael Bader

From the Max Delbrück Center for Molecular Medicine (M.S., M. Böhm, G.B., D.G., M. Bader) and the Franz Volhard Clinic (M. Böhm), Berlin-Buch, Germany.

Abstract The renin-angiotensin system plays a pivotal role in blood pressure regulation. Recent molecular biological findings led to the new concept that in addition to the classic endocrine system, local tissue systems may also play an important role in cardiovascular diseases such as hypertension. In particular, the brain renin-angiotensin system was shown to influence the central control of blood pressure and is thought to contribute to the hypertensive phenotype of genetically hypertensive rat models. To identify the physiological role of these local systems, we established an antisense strategy to downregulate the expression of the precursor hormone angiotensinogen (AOGEN) in cell culture, which can also be used to establish transgenic rat lines. Plasmids encoding an RNA sequence complementary to the rat AOGEN mRNA under control of different viral and tissue-specific promoters were constructed and transfected into an AOGEN-expressing cell line. A competitive reverse transcription–polymerase chain reaction method was established for the quantification of AOGEN mRNA. Depending on the level of antisense RNA, the expression of the AOGEN gene was reduced down to 22% of control levels. Furthermore, the secretion of AOGEN protein was totally abolished. These results clearly demonstrate that the antisense constructs used are functional in reducing the AOGEN gene expression in vivo and can be used for the production of transgenic rats.

Key Words: DNA, antisense • AOGEN • carcinoma, hepatocellular • gene expression regulation

This article has been cited by other articles:

				D. I. Diz Lewis K. Dahl Memorial Lecture: The Renin-Angiotensin System and Aging Hypertension, July 1, 2008; 52(1): 37 - 43. [Full Text] [PDF]

				N. R. Shih, O. D. Jo, and N. Yanagawa Effects of PHEX Antisense in Human Osteoblast Cells J. Am. Soc. Nephrol., February 1, 2002; 13(2): 394 - 399. [Abstract] [Full Text] [PDF]

				M. Schinke, O. Baltatu, M. Bohm, J. Peters, W. Rascher, G. Bricca, A. Lippoldt, D. Ganten, and M. Bader Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen PNAS, March 30, 1999; 96(7): 3975 - 3980. [Abstract] [Full Text] [PDF]

				M. I. Phillips Is Gene Therapy for Hypertension Possible? Hypertension, January 1, 1999; 33(1): 8 - 13. [Full Text] [PDF]

				P. F. Dillon, R. S. Root-Bernstein, and D. D. Holsworth Augmentation of Aortic Ring Contractions by Angiotensin II Antisense Peptide Hypertension, March 1, 1998; 31(3): 854 - 860. [Abstract] [Full Text] [PDF]

				M. I. Phillips Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension Hypertension, January 1, 1997; 29(1): 177 - 187. [Abstract] [Full Text] [PDF]